Euroscreen completes enrolment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes

Gosselies, Belgium: 14 September 2016 - Euroscreen announced today that it has completed enrolment for its Phase II proof-of-concept clinical study designed to evaluate ESN364, an oral, small molecule NK3 antagonist, for the treatment of Menopausal Hot Flashes.

The double-blind, placebo controlled 12-week study will measure the efficacy of ESN364 in reducing the severity and frequency of Menopausal Hot Flashes in symptomatic menopausal women. The study has enrolled a total of 87 patients at various clinical sites in Belgium and final data are expected by year end 2016.

SN364 has already successfully completed a Phase I study in men and women demonstrating an excellent safety profile as well as clear drug efficacy on hormone biomarkers. In addition, pre-clinical proof-of-concept studies have shown the ability of ESN364 to specifically block the occurrence of Hot Flashes.

More info on Euroscreen's website.

Next > Bluebee expands into the U.S.

Previous > Mainstay Medical’s ReActiv8-B Clinical Trial for treatment of Chronic Low Back Pain enrols First Subject